Literature DB >> 7967147

[Clinical significance of microalbuminuria in elderly diabetic patients].

Y Ikeda1, H Yamashita, K Takamatsu, K Hashimoto.   

Abstract

To clarify the clinical significance of microalbuminuria in elderly diabetic patients, 167 diabetic patients were divided into two groups, 81 elderly patients aged 65 or more (mean age +/- SD: 72 +/- 9, 31 men and 50 women) and 86 middle-aged patients less than 65 years (mean age +/- SD: 56 +/- 8, 49 men and 37 women). We then examined the prevalence of microalbuminuria and other clinical parameters in both groups. The duration of diabetes (10 +/- 7 vs 9 +/- 7 years), body mass index (24.3 +/- 4.1 vs 23.9 +/- 3.5) and the levels of fasting plasma glucose (142 +/- 38 vs 144 +/- 40 mg/dl), HbA1c (7.4 +/- 1.6 vs 7.8 +/- 1.6%), plasma cholesterol (203 +/- 34 vs 212 +/- 46 mg/dl) and triglyceride (117 +/- 57 vs 121 +/- 67 mg/dl) showed no significant difference between elderly and middle-aged patients. However, the prevalence of microalbuminuria (30 < or = urinary albumin level < 300 mg/g.Cr), macroangiopathies involving cerebrovascular disease, ischemic heart disease and atherosclerosis obliterans, and hypertension were higher in elderly patients than those in the middle-aged patients (43.2 vs 20.0%, chi 2 = 10.39, p < 0.01, 29.6 vs 10.5%, chi 2 = 9.66, p < 0.01, 42.0 vs 24.4, chi 2 = 5.82, p < 0.05, respectively). Microalbuminuria in elderly patients may be caused not only by diabetic glomerular changes but also by glomerular changes due to aging and hypertension. Microalbuminuria, macroangiopathies and hypertension in elderly diabetic patients may develop interrelatedly depending on common vascular damages due to diabetes and aging.

Entities:  

Mesh:

Year:  1994        PMID: 7967147     DOI: 10.3143/geriatrics.31.616

Source DB:  PubMed          Journal:  Nihon Ronen Igakkai Zasshi        ISSN: 0300-9173


  1 in total

1.  Renal status in elderly patients with type 2 diabetes.

Authors:  Kazunaga Takamatsu
Journal:  Clin Exp Nephrol       Date:  2019-09-23       Impact factor: 2.801

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.